Silmitasertib - Senhwa Biosciences
Alternative Names: CX 4945Latest Information Update: 23 Aug 2024
At a glance
- Originator Cylene Pharmaceuticals
- Developer Cylene Pharmaceuticals; Penn State College of Medicine; Senhwa Biosciences; Stanford University School of Medicine
- Class 3-ring heterocyclic compounds; Antineoplastics; Antivirals; Carboxylic acids; Naphthyridines; Small molecules
- Mechanism of Action Casein kinase II inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Community-acquired pneumonia; COVID 2019 infections
- Phase I/II Cholangiocarcinoma; Medulloblastoma
- Phase I Basal cell cancer
- Preclinical Acute myeloid leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
- No development reported Giant lymph node hyperplasia; Multiple myeloma; Solid tumours
Most Recent Events
- 09 Aug 2024 Senhwa Biosciences plans a phase I/II trial in Solid tumors (Second-line therapy, Children, Adolescents, Adults, Combination therapy) (PO) in September 2024 (NCT06541262)
- 06 Aug 2024 Senhwa Biosciences receives "Study May Proceed" letter from the US FDA for the phase I/II trial in Solid tumors
- 11 Jul 2024 Senhwa Biosciences announces intention to apply for Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPD) for Silmitasertib for Neuroblastoma